Home Compare GSK.L vs MRK
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Merck & Co.: Which Stock Looks Stronger in 2026?

The structural profiles are close, with GSK carrying a narrow edge on growth. Merck still has the edge on profitability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The comparison is mainly decided in growth, with the rest of the profile carrying less weight.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and MRK share the same industry classification.

For a similarity-based comparison, see how GSK and Merck each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh
vs
MRK
Merck & Co., Inc.
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in growth.

Dimension spread: GSK.L vs MRK Profitability 46 62 Stability 69 57 Valuation 80 88 Growth 71 31 GSK.L MRK
Gap Ranking
#1 Growth +40
#2 Profitability +16
#3 Stability +12
#4 Valuation +8
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and MRK Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LMRK Relative valuation Structural strength

GSK plc looks stronger, but the price setup still looks more supportive for Merck & Co., Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, GSK plc ranks near the top of the group; Merck & Co., Inc. sits in the weaker half.
Profitability
On profitability, the edge still sits with Merck & Co., Inc., even though both profiles look solid.
Growth — Dominant Gap
GSK.L
71
MRK
31
Gap+40in favour of GSK.L

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Profitability still favours Merck, with a 13.8-point operating margin advantage keeping the comparison from looking fully resolved.

What this means for the comparison

Growth is the clearest driver of the lead, with profitability adding further support — though profitability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the GSK.L vs MRK comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how GSK.L and MRK each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.